Related Experiment Videos
Transgenic animal models for Alzheimer's disease
K Fukuchi1, C E Ogburn, A C Smith
1Department of Pathology, University of Washington, Seattle 98195.
Annals of the New York Academy of Sciences
|September 24, 1993
Summary
Alzheimer's disease involves beta-amyloid protein deposits. While in vitro studies show neurotoxicity, transgenic mice models do not fully replicate Alzheimer's pathology, suggesting in vivo protective factors.
Area of Science:
- Neuroscience
- Molecular Biology
- Genetics
Background:
- Alzheimer's disease (AD) neuropathology is marked by beta-amyloid (Aβ) protein aggregates.
- Mutations in the gene for amyloid precursor protein (APP) are linked to familial AD.
- In vitro studies indicate neurotoxicity of APP derivatives.
Purpose of the Study:
- To investigate the discrepancy between in vitro and in vivo models of Alzheimer's disease.
- To explore potential in vivo suppressors of beta-amyloid precursor protein derivative-mediated neurotoxicity.
Main Methods:
- Review of existing literature on Alzheimer's disease neuropathology.
- Analysis of transgenic mouse models overexpressing APP or its fragments.
- Comparison of in vitro neuronal cell culture findings with in vivo animal model outcomes.
Main Results:
- Familial Alzheimer's disease is associated with mutations in the amyloid precursor protein gene.
- Overexpression of APP or its fragments in vitro causes neuronal degeneration.
- Transgenic mouse models have not consistently replicated the pathological hallmarks of Alzheimer's disease observed in patients.
Conclusions:
- A significant difference exists between in vitro and in vivo models regarding APP derivative neurotoxicity.
- The lack of pathology in transgenic mice suggests the presence of in vivo suppressors.
- Further research is needed to identify these suppressors and understand their role in mitigating neurotoxicity.